CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

Context for CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) trades around US$49.51, with recent returns ranging from a 1 day gain of about 1.4% to a past month decline of roughly 13.6% and a past ...

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an ...

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a ...

Synthego, a pioneering leader in genome engineering solutions, today announced that the Supreme Court of the United States has denied a petition for a writ of certiorari from Agilent Technologies, Inc ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $49.51, demonstrating a +1.43% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.